Fractyl Health’s GLP-1-based pancreatic gene therapy has outperformed semaglutide injections for weight loss—at least in mice. In a presentation Oct. 4 at the annual conference of the European ...

With the gold rush in obesity meds showing no sign of abating, Fractyl Health is gearing up to go public as it gathers preclinical evidence that its GLP-1 gene therapy could take on Novo Nordisk’s ...

Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 10 Best New Penny Stocks to Invest In. On December 19, Canaccord Genuity reiterated its Buy rating on Fractyl Health, Inc. (NASDAQ:GUTS) with a price ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today ...

13-week follow-up represents the longest data to-date demonstrating durable efficacy of RJVA-001 on weight and blood sugar in the diet-induced obesity (DIO) mouse model Company plans to use durable ...

BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat ...

(Reuters) - Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million. After a two-year lull, initial ...

Rajagopalan outlined an upcoming "3-month randomized data readout" for the REMAIN-1 midpoint cohort next month, with "6-month randomized data from this cohort in the first quarter of 2026." Additional ...

Data show nutrient-responsive GLP-1 secretion in human beta cells and human islets, demonstrating that Rejuva mimics natural hormone regulation rather than constant drug-driven stimulation Rejuva ...

FRACTYL HEALTH ($GUTS) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$0.52 per share, missing estimates of -$0.44 by $0.08 ...

Fractyl Announces New Clinical Data on the Mechanism of Revita DMR in Type 2 Diabetes Data presented at ENDO 2020 from the randomized, sham-controlled REVITA-2 study verifies that improvements in ...